Home > Journals > Minerva Endocrinologica > Past Issues > Minerva Endocrinologica 2001 September;26(3) > Minerva Endocrinologica 2001 September;26(3):149-58

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA ENDOCRINOLOGICA

A Journal on Endocrine System Diseases


Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,118


eTOC

 

  NEW DIAGNOSTIC AND THERAPEUTIC STRATEGIES: SOMATOSTATIN ANALOGS. Part I


Minerva Endocrinologica 2001 September;26(3):149-58

language: Italian

Somatostatin receptors in non-endocrine tumours

Casini Raggi C., Pinzani P., Gelmini S., Tricarico C., Orlando C., Calabrò A., Renzi D., Cianchi F., Valanzano R., Distante V., Cortesini C., Tonelli F., Cataliotti L., Cameron Smith M., Messerini L., Bianchi S., Pazzagli M., Serio M., Maggi M.


PDF  


The study of the antiproliferative action of so-matostatin (ss) is important not only to understand the regulation of neuroendocrine tumours that express receptors (sst), but also non-endocrine tumours which express these receptors. We previously demonstrated the presence of sst2 in a wide panel of cell lines from human neuroblastoma. Although hypotheses have been put forward that treatment with ss or its analogs may be beneficial in oncological patients, this does not appear to be the case in neuroblastoma; patients with high sst2 levels (who are therefore ''sensitive'' to ss treatment) have per se a relatively positive outcome. Therefore, adjuvant treatment with ss is not necessary. Viceversa, patients with a poor prognosis are essentially characterized by a low expression of sst2 (and therefore are ''insensitive'' to a therapy with ss). In these patients adjuvant treatment with ss might be indicated, but would have little chance of success. Although the majority of neuroendocrine tumours expresses sst2, pancreas and prostate cancer express sst1 but not sst2, and are therefore insensitive to octreotide treatment which binds preferentially to sst2. Tumours like colorectal carcinoma and breast cancer also express sst2 in their more favourable forms. However, the concentration of sst2 in colorectal cancer is similar, if not lower than that in the surrounding normal tissue. Therefore, the probability of successful adjuvant therapy with ss is relatively low. In breast cancer, it is possible that sensitivity to estrogens may have a positive influence on the expression of sst2. This might justify clinical trials with ss in breast cancer.

top of page

Publication History

Cite this article as

Corresponding author e-mail